Search 

Evercore (NYSE:EVR) is a leading independent investment banking advisory firm. Evercore’s Investment Banking business advises its clients on mergers, acquisitions, divestitures, restructurings, financings, public offerings, private placements and other strategic transactions and also provides institutional investors with high quality equity research, sales and trading execution that is free of the conflicts created by proprietary activities. Evercore’s Investment Management business comprises wealth management, institutional asset management and private equity investing. Evercore serves a diverse set of clients around the world from 28 offices in North America, Europe, South America and Asia. More information about Evercore can be found on the Company’s website at www.evercore.com. 


Investment Banking 

- Corporate Advisory 
- Restructuring Advisory 
- Evercore ISI 
- Private Funds Group 
- Private Capital Advisory 


Investment Management 

- Institutional Asset Management 
• Atalanta Sosnoff Capital 
• Evercore Trust Company 
• Evercore Casa de Bolsa 

- Wealth Management 
• Evercore Wealth Management 

- Private Equity 
• Evercore Mexico Capital Partners 
• Trilantic Capital Partners

Exsight Capital is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions.

Research Interest:

• Using targeted mutagenesis and mouse genetics to study how the brain functions.
  The brain interprets the world through five major modalities of sensation.
  Information for sight, sound, taste and touch are relayed to the brain through networks of cellular or neuronal connections.
  
  The sense of smell (olfaction); however, uses specialized bipolar neurons, which can simultaneously identify odors with their dendritically located cilia and make direct connections to the brain with their axonal projections. Thus, olfactory neurons directly convert stimuli from the external world into an internal representation within the brain. In a surprising twist, the same protein (the odorant receptor) that is used for identifying odors is also used for guiding the axonal connection to the brain. The olfactory system detects the universe of odors through ~1000 different odorant receptor coding genes. But, each olfactory neuron makes only one type of odorant receptor. The distribution of neuron types is scattered across the interior lining of the nose, but their axonal projections to the brain are sorted out into discrete units that represent each neuronal type.
  
  To examine how the odorant receptor (OR) functions in odor detection and axonal projections, I have used mouse embryonic stem cell technology coupled with genetic manipulation to alter the expressed OR proteins. Studying these modified OR proteins in vivo, I have found that several additional processes within the neuron are affected. The observed one OR gene expressed per olfactory neuron is maintained even if additional OR genes are added to the genome. I am interested in understanding how olfactory neurons control OR gene expression and how the OR protein provides specificity for axonal projections to form discrete units in the brain.

Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology –quiescent (sleeping) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant cancers: pancreatic, colorectal, non-small cell lung, and ovarian.

Recently, it has become accepted in the scientific community that populations of malignant cells are not homogenous, they have hierarchy.  Some of the cancer cells divide rapidly but some do not, some of the cancer cells are sleeping. They are in the quiescent state. This is especially true of solid tumors in which the cells in the outer layers are proliferating, but the inner volume comprises a large proportion of quiescent cells, frequently as a result of inadequate nutrient supply and oxygen deprivation (hypoxia). Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia, as a target for chemotherapy, is currently an active area of research.

Moreover, when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer cells often go to “sleep”, or use quiescent as a niche to hide.  After the completion of treatment, these cells can acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.

Fox Rothschild LLP is a national law firm with more than 600 attorneys practicing in 21 offices coast to coast. We’ve been serving clients for more than a century, and we’ve been climbing the ranks of the nation’s largest firms for many years, according to both The Am Law 100 and The National Law Journal. 

Our lawyers provide a full range of legal services to public and private companies – from family-run businesses to multinational corporations. We also represent charitable, medical and educational institutions both in the United States and in more than 50 countries worldwide.

We’re smart. We’re solid. We’re established. But we believe we’re also a bit different from many other law firms — and we’re proud of it.

We’re entrepreneurial. We’re resourceful. We’re nimble. It’s those qualities that clients tell us they value in their lawyers — and that have allowed us to build a firm of bright, creative, responsive attorneys with solid legal know-how and valuable industry experience.

Our lawyers partner with clients and work hand-in-hand with them to keep pace with their business objectives and anticipate the challenges ahead. Our entrepreneurial approach — as a firm that works in the trenches with clients, helping them to achieve their goals — is a characteristic that differentiates us. When you choose Fox, you gain an advisor that will be as dedicated to your success as you are.

French BioBeach is a Life Science Catalyst between France & Southern California, Enabling and Fostering Business Relationships. We work with SoCal companies on their European Expansion and with French companies on their US expansion. We facilitate Partnering Opportunities and/or Physical Implantation (incubator).

WHO WE ARE The French-American Biotechnology Springboard (FABS) is a steering committee developed in collaboration with the French-American Chamber of Commerce of New England [FACCNE] to guide French Bio-Entrepreneurs in the highly specific scientific, business and cultural New England environment. The Group is comprised of American and French professional volunteers with complementary backgrounds and competencies, who have had and/or are currently holding positions in Massachusetts-based Biotechnology and Pharmaceutical Companies.   WHAT WE DO -Mentoring French companies that are evaluating or have decided to start their business in the New England. -Guiding the French Bio-Entrepreneurs first installation steps, sharing their experience and expertise and facilitates their development by leveraging the local expertise of a dynamic network of professionals. -Supporting FACCNE life sciences activities with a yearly FACCNE Biotech meeting in March. -Coaching start ups/Institutions to better prepared to the US market during French biotech tours (presentations, one on one coaching). -Helping US Companies to explore / connect with French market through participation to programs such as the Boston based Office for Science and Technology - accelerator designed to help entrepreneurs grow their business in France and Europe.

Fosters, develops and commercializes healthcare and life sciences technology.